Search research articles
Contact Us
Filters
Showing results (261-270 of 379) with videos related to
Page
of 38
Sort By:
The Cochrane Database of Systematic Reviews
|
January 14, 2020
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
Angela Aldin, Lisa Umlauff, Lise J Estcourt, et al.
European Journal of Human Genetics : EJHG
|
September 18, 2014
Heritability estimates on Hodgkin's lymphoma: a genomic- versus population-based approach
Hauke Thomsen, Miguel Inacio da Silva Filho, Asta Försti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity
Boris Böll, Farag Eltaib, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group
Dennis A Eichenauer, Henning Bredenfeld, Heinz Haverkamp, et al.
Blood
|
October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Holger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Molecular Cancer Therapeutics
|
April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma
Ron D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
Clinical Pharmacokinetics
|
March 23, 2007
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
Stefan Wilde, Alexander Jetter, Stephan Rietbrock, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
September 12, 2014
Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?
Frank Lohr, Dietmar Georg, Luca Cozzi, et al.
Hematological Oncology
|
March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
Dennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Leukemia & Lymphoma
|
July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant
Simon J Harrison, Andy K Hsu, Paul Neeson, et al.
Page
of 38
Search research articles
Search
Showing results (261-270 of 379) with videos related to
Sort By:
Page
of 38
The Cochrane Database of Systematic Reviews
|
January 14, 2020
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies
Angela Aldin, Lisa Umlauff, Lise J Estcourt, et al.
European Journal of Human Genetics : EJHG
|
September 18, 2014
Heritability estimates on Hodgkin's lymphoma: a genomic- versus population-based approach
Hauke Thomsen, Miguel Inacio da Silva Filho, Asta Försti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2009
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity
Boris Böll, Farag Eltaib, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group
Dennis A Eichenauer, Henning Bredenfeld, Heinz Haverkamp, et al.
Blood
|
October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Holger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Molecular Cancer Therapeutics
|
April 29, 2011
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma
Ron D Jachimowicz, Giulio Fracasso, Paul J Yazaki, et al.
Clinical Pharmacokinetics
|
March 23, 2007
Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity
Stefan Wilde, Alexander Jetter, Stephan Rietbrock, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
September 12, 2014
Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?
Frank Lohr, Dietmar Georg, Luca Cozzi, et al.
Hematological Oncology
|
March 21, 2022
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group
Dennis A Eichenauer, Ina Bühnen, Annette Plütschow, et al.
Leukemia & Lymphoma
|
July 5, 2013
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant
Simon J Harrison, Andy K Hsu, Paul Neeson, et al.
Page
of 38